Search Results - "Szymura, Szymon J"

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial by Szymura, Szymon J., Wang, Lin, Zhang, Tiantian, Cha, Soung-chul, Song, Joo, Dong, Zhenyuan, Anderson, Aaron, Oh, Elizabeth, Lee, Vincent, Wang, Zhe, Parshottam, Sapna, Rao, Sheetal, Olsem, Jasper B., Crumpton, Brandon N., Lee, Hans C., Manasanch, Elisabet E., Neelapu, Sattva, Kwak, Larry W., Thomas, Sheeba K.

“…Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human,…”
Get full text

DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-κB and sensitize to alkylating chemotherapy by Szymura, Szymon J, Bernal, Giovanna M, Wu, Longtao, Zhang, Zhongqin, Crawley, Clayton D, Voce, David J, Campbell, Paige-Ashley, Ranoa, Diana E, Weichselbaum, Ralph R, Yamini, Bakhtiar

“…Nuclear factor-κB (NF-κB) plays a prominent role in promoting inflammation and resistance to DNA damaging therapy. We searched for proteins that modulate the…”
Get full text

NF-κB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small cell lung cancer by Szymura, Szymon J, Zaemes, Jacob P, Allison, David F, Clift, Sheena H, D'Innocenzi, Jaclyn M, Gray, Lisa G, McKenna, Brian D, Morris, Benjamin B, Bekiranov, Stefan, LeGallo, Robin D, Jones, David R, Mayo, Marty W

“…Epithelial-to-mesenchymal transition (EMT) results in changes that promote de-differentiation, migration, and invasion in non-small cell lung cancer (NSCLC)…”
Get full text

Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma by Voce, David J, Bernal, Giovanna M, Wu, Longtao, Crawley, Clayton D, Zhang, Wei, Mansour, Nassir M, Cahill, Kirk E, Szymura, Szymon J, Uppal, Abhineet, Raleigh, David R, Spretz, Ruben, Nunez, Luis, Larsen, Gustavo, Khodarev, Nikolai N, Weichselbaum, Ralph R, Yamini, Bakhtiar

“…Alkylating chemotherapy is a central component of the management of glioblastoma (GBM). Among the factors that regulate the response to alkylation damage,…”
Get full text

CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia by Wang, Xiuli, Dong, Zhenyuan, Awuah, Dennis, Chang, Wen-Chung, Cheng, Wesley A., Vyas, Vibhuti, Cha, Soung-Chul, Anderson, Aaron J., Zhang, Tiantian, Wang, Zhe, Szymura, Szymon J., Kuang, Benjamin Z., Clark, Mary C., Aldoss, Ibrahim, Forman, Stephen J., Kwak, Larry W., Qin, Hong

“…Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in B-cell malignancies including acute lymphoblastic leukemia (ALL),…”
Get full text

Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer by Wamsley, J Jacob, Kumar, Manish, Allison, David F, Clift, Sheena H, Holzknecht, Caitlyn M, Szymura, Szymon J, Hoang, Stephen A, Xu, Xiaojiang, Moskaluk, Christopher A, Jones, David R, Bekiranov, Stefan, Mayo, Marty W

“…Soluble growth factors and cytokines within the tumor microenvironment aid in the induction of the epithelial-to-mesenchymal transition (EMT). Although EMT…”
Get full text

DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-?B and sensitize to alkylating chemotherapy by Szymura, Szymon J, Bernal, Giovanna M, Wu, Longtao, Zhang, Zhongqin, Crawley, Clayton D, Voce, David J, Campbell, Paige-Ashley, Ranoa, Diana E, Weichselbaum, Ralph R, Yamini, Bakhtiar

“…Nuclear factor-?B (NF-?B) plays a prominent role in promoting inflammation and resistance to DNA damaging therapy. We searched for proteins that modulate the…”
Get full text

Temozolomide treatment induces lncRNA MALAT1 in an NF-кB and p53 co-dependent manner in glioblastoma by Voce, David J., Bernal, Giovanna M., Wu, Longtao, Crawley, Clayton D., Zhang, Wei, Mansour, Nassir M., Cahill, Kirk E., Szymura, Szymon J., Uppal, Abhineet, Raleigh, David R., Spretz, Ruben, Nunez, Luis, Larsen, Gustavo, Khodarev, Nikolai N., Weichselbaum, Ralph R., Yamini, Bakhtiar

“…Alkylating chemotherapy is a central component of the management of glioblastoma (GBM). Among the factors that regulate the response to alkylation damage,…”
Get full text